search
Back to results

Effect of Periodontal Therapy on Biomarkers in Periodontitis

Primary Purpose

Periodontal Health, Periodontitis

Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Non-surgically performed scaling and root planing
Sponsored by
Marmara University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Periodontal Health focused on measuring periodontitis, periodontal treatment

Eligibility Criteria

23 Years - 51 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. systemically healthy and non-smoker individuals
  2. having ≥20 teeth present (except third molars)
  3. individuals with periodontally healthy, periodontitis stage III grade B and C diagnoses

Exclusion Criteria:

  1. having any diagnosed medical disorders such as diabetes mellitus, cardiovascular diseases, rheumatoid arthritis, immunological and mucocutaneous diseases
  2. usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months
  3. having any non-inflammatory destructive periodontal disease
  4. nonsurgical/surgical periodontal therapy received in the past year
  5. pregnant/ lactating/ postmenopausal females.

Sites / Locations

  • Marmara University, Faculty of Dentistry, Department of Periodontology

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Active Comparator

Active Comparator

Arm Label

Periodontal healthy

Periodontitis Stage III Grade B

Periodontitis Stage III Grade C

Arm Description

The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.

The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.

Outcomes

Primary Outcome Measures

Salivary MMP-8 (ng/ml) level
change in salivary MMP-8 levels from baseline to 1 month and 3 months after treatment
Salivary MAF (ng/ml) level
change in salivary MAF levels from baseline to 1 month and 3 months after treatment
Salivary MIP-1α (pg/ml) level
change in salivary MIP-1α levels from baseline to 1 month and 3 months after treatment
Salivary M-CSF (pg/ml) level
change in salivary M-CSF levels from baseline to 1 month and 3 months after treatment
Salivary IL-34 (pg/ml) level
change in salivary M-CSF levels from baseline to 1 month and 3 months after treatment

Secondary Outcome Measures

Serum MMP-8 (ng/ml) level
change in serum MMP-8 levels from baseline to 1 month and 3 months after treatment
Serum MAF /ng/ml) level
change in serum MAF levels from baseline to 1 month and 3 months after treatment
Serum MIP-1α (pg/ml) level
change in serum MIP-1α levels from baseline to 1 month and 3 months after treatment
Serum M-CSF (pg/ml) level
change in serum M-CSF levels from baseline to 1 month and 3 months after treatment
Serum IL-34 (pg/ml) level
change in serum IL-34 levels from baseline to 1 month and 3 months after treatment

Full Information

First Posted
July 29, 2021
Last Updated
August 6, 2021
Sponsor
Marmara University
search

1. Study Identification

Unique Protocol Identification Number
NCT05005923
Brief Title
Effect of Periodontal Therapy on Biomarkers in Periodontitis
Official Title
Effect of Non-Surgical Periodontal Therapy on Salivary and Serum Biomarkers in Stage III Grade B and C Periodontitis
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
January 23, 2019 (Actual)
Primary Completion Date
July 24, 2020 (Actual)
Study Completion Date
July 24, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Marmara University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The present study aimed to assess the effect of non-surgical periodontal treatment on serum and salivary MMP-8, MAF, MIP-1α, M-CSF, and IL34 levels in periodontitis stage III grade B (P-III-B) and C (P-III-C) patients. 20 periodontally healthy, 20 P-III-B and 25 P-III-C participants were enrolled. At baseline, serum and saliva samples were collected and the whole mouth clinical periodontal parameters were recorded. Periodontitis patients received non-surgical periodontal treatment. Clinical parameters were re-measured and samples were re-collected at 1 and 3 months after treatment. Serum and salivary MMP-8, MAF, MIP-1α, M-CSF, and IL34 levels were analyzed by ELISA. Data were analyzed using appropriate statistical tests.
Detailed Description
Periodontal disease is an inflammatory process that can result in tooth loss and also is considered a modifying factor for systemic health. Matrix metalloproteinase (MMP)-8 is the major collagenase of periodontal tissue breakdown. Macrophage-activating factor (MAF) can activate macrophages. M-CSF is known to modulate disease and inflammation and to play an important role in bone destruction. IL-34 shares vital functions of M-CSF, and manages myeloid cell survival, differentiation, and proliferation. This study is the first controlled clinical study that examines the levels of MIP-1α, MAF, MMP-8, M-CSF, IL-34 in saliva and serum in two different periodontitis, and evaluates the situation before and after the treatment. The first hypothesis of this study; in periodontitis group, salivary and serum MIP-1α, MAF, MMP-8, M-CSF, IL-34 levels will be high, in contrast to the periodontal healthy group. The second hypothesis of this study is that after periodontal treatment, saliva and serum MIP-1α, MAF, MMP-8, M-CSF, IL-34 levels will decrease. Based on these hypotheses, the aim of the study is; to compare the levels of MIP-1a, MAF, MMP-8, M-CSF, IL-34 in saliva and serum of healthy controls, P-III-B, and P-III-C subjects and to evaluate the effect of periodontal treatment. A total of 65 systemically healthy patients; 20 periodontally healthy, 20 P-III-B, 25 P-III-C were included in this study. The whole mouth clinical periodontal examination included measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. The presence and type of the alveolar bone loss were assessed on the digital panoramic radiograph in each participant, which was supplemented with periapical radiographs if necessary. Periodontal status of each patient was evaluated by a single calibrated periodontists with a manual probe. The diagnosis of periodontitis or periodontally health was determined according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Periodontally healthy individuals (n=20) in the control group had no sites with PD >3 mm and CAL >2 mm and also no radiographic evidence of alveolar bone loss. BOP was <10% in the whole mouth. Healthy group also exhibited no history of periodontitis. The periodontitis stage III patients had a minimum three teeth apart from the first molars and incisors showing CAL ≥5 mm and PD ≥6 mm and showed no>4 teeth loss because of periodontitis. Radiographic bone loss extending from coronal to middle third or beyond. Radiographic bone loss was determined from the tooth showing the most severe bone loss as a percentage of root length. If the values of bone loss %/age were between 0.25 and 1.0, the patients were assigned to grade B (n=20). If higher than 1.0, the patients were assigned to grade C (n=25) Treatment The recruited periodontitis patients received conventional quadrant scaling and root planning (SRP) under local anesthesia in a total of 4 sessions in two weeks. SRP was performed by the same periodontist using ultrasonic inserts and manual periodontal curettes. Re-evaluations were performed at 1 and 3 months following the completion of the SRP. No periodontal intervention was carried out in the periodontally healthy controls. Saliva and Serum Sampling A total of 5 mL of unstimulated whole saliva was collected by passive drool method between 9:00 and 10:00 am. The participants were advised to avoid food consumption for three hours before sample collection. The participants were seated upright and saliva was collected over a period of 5 minutes with instructions to pool saliva in the floor of the mouth and passively drool it into a sterile glass beaker. Then saliva samples are immediately transferred to a 2 mL polypropylene tube and stored at -80°C. A total of 5 mL of blood was collected from the antecubital fossa by venepuncture method. Serum was isolated from the blood by centrifuging at 5000 rpm for 10 minutes followed by its rapid transfer to a sterile polypropylene tube and storage at -80°C. Biomarker Immunoassays Saliva and serum samples were thawed on ice. The saliva samples were centrifuged at 5.000 rpm for 15 minutes at room temperature, and supernatants were immediately used for assays. Serum and salivary samples of MMP-8 , M-CSF*, MIP-1α*, MAF , IL-34 in were measured by ELISA using commercial kits. Statistical Analysis All statistical analyses were carried out with the standard statistical software package. For the intra-group comparisons, if the data were not normally disturbed, Friedman test and the Dunn test with the Bonferroni correction were used to analyze the change between baseline and 1 month and 3 months after treatment. For inter-group comparisons, Mann-Whitney U test for normally and non-normally disturbed data. The Spearman's rank correlation test was used to detect the correlations of biochemical parameters with clinical parameters and each others in diseased group before and after treatment. All tests were performed at significance level of P <0.05.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Periodontal Health, Periodontitis
Keywords
periodontitis, periodontal treatment

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
65 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Periodontal healthy
Arm Type
No Intervention
Arm Title
Periodontitis Stage III Grade B
Arm Type
Active Comparator
Arm Description
The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
Arm Title
Periodontitis Stage III Grade C
Arm Type
Active Comparator
Arm Description
The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks.
Intervention Type
Procedure
Intervention Name(s)
Non-surgically performed scaling and root planing
Intervention Description
Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
Primary Outcome Measure Information:
Title
Salivary MMP-8 (ng/ml) level
Description
change in salivary MMP-8 levels from baseline to 1 month and 3 months after treatment
Time Frame
baseline to 1 month and 3 months after treatment
Title
Salivary MAF (ng/ml) level
Description
change in salivary MAF levels from baseline to 1 month and 3 months after treatment
Time Frame
baseline to 1 month and 3 months after treatment
Title
Salivary MIP-1α (pg/ml) level
Description
change in salivary MIP-1α levels from baseline to 1 month and 3 months after treatment
Time Frame
baseline to 1 month and 3 months after treatment
Title
Salivary M-CSF (pg/ml) level
Description
change in salivary M-CSF levels from baseline to 1 month and 3 months after treatment
Time Frame
baseline to 1 month and 3 months after treatment
Title
Salivary IL-34 (pg/ml) level
Description
change in salivary M-CSF levels from baseline to 1 month and 3 months after treatment
Time Frame
baseline to 1 month and 3 months after treatment
Secondary Outcome Measure Information:
Title
Serum MMP-8 (ng/ml) level
Description
change in serum MMP-8 levels from baseline to 1 month and 3 months after treatment
Time Frame
baseline to 1 month and 3 months after treatment
Title
Serum MAF /ng/ml) level
Description
change in serum MAF levels from baseline to 1 month and 3 months after treatment
Time Frame
baseline to 1 month and 3 months after treatment
Title
Serum MIP-1α (pg/ml) level
Description
change in serum MIP-1α levels from baseline to 1 month and 3 months after treatment
Time Frame
baseline to 1 month and 3 months after treatment
Title
Serum M-CSF (pg/ml) level
Description
change in serum M-CSF levels from baseline to 1 month and 3 months after treatment
Time Frame
baseline to 1 month and 3 months after treatment
Title
Serum IL-34 (pg/ml) level
Description
change in serum IL-34 levels from baseline to 1 month and 3 months after treatment
Time Frame
baseline to 1 month and 3 months after treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
23 Years
Maximum Age & Unit of Time
51 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: systemically healthy and non-smoker individuals having ≥20 teeth present (except third molars) individuals with periodontally healthy, periodontitis stage III grade B and C diagnoses Exclusion Criteria: having any diagnosed medical disorders such as diabetes mellitus, cardiovascular diseases, rheumatoid arthritis, immunological and mucocutaneous diseases usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months having any non-inflammatory destructive periodontal disease nonsurgical/surgical periodontal therapy received in the past year pregnant/ lactating/ postmenopausal females.
Facility Information:
Facility Name
Marmara University, Faculty of Dentistry, Department of Periodontology
City
Istanbul
Country
Turkey

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Effect of Periodontal Therapy on Biomarkers in Periodontitis

We'll reach out to this number within 24 hrs